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Abstract
Nonalcoholic fatty liver disease is increasingly regarded as a hepatic manifestation of metabolic syndrome, and the 
severity of nonalcoholic fatty liver disease seems to increase in parallel with other features of metabolic syndrome. 
Excess lipid accumulation in the liver cells is not only a mediator of Metabolic Syndrome and indicator of a lipid 
overload but also accompanied by a range of histological alterations varying from 'simple' steatosis to nonalcoholic 
steatohepatitis, with time progressing to manifest cirrhosis. Hepatocellular carcinoma may also occur in nonalcoholic 
steatohepatitis -related cirrhosis with a mortality rate similar to or worse than for cirrhosis associated with hepatitis C. 
This review summarizes the knowledge about the causal relationship between hepatic fat accumulation, insulin 
resistance, liver damage and the etiological role of hepatic fat accumulation in pathogenesis of extra- and intra-hepatic 
manifestations. Special emphasis is given suggestions of new targets treatment and prevention of nonalcoholic fatty 
liver disease.
Introduction
Nonalcoholic fatty liver disease (NAFLD), no more than 
15 years ago considered as rare, has now reached epi-
demic propertions in China and has a major clinical and 
research priority [1]. It is only since a decade or so that 
nonalcoholic fatty liver disease is considered to be a man-
ifestations of insulin resistance[2,3]. The fact that insulin 
resistance and compensatory hyperinsulinaemia have 
central etiologic roles in the development of both meta-
bolic syndrome and NAFLD makes the excessive accu-
mulation of triglycerides (TG) in the liver especially 
interesing [4]. The severity of NAFLD increases in paral-
lel with other features of the metabolic syndrome, sup-
porting that NAFLD is its hepatic manifestation [5].
Although current therapy presently is limited to sugges-
tions of lifestyle changes and control of associated meta-
bolic disorders, experimental studies and clinical 
observations do suggest also other modalities of treat-
ment. As an example, a proof-of-concept study suggest 
that administration of pioglitazone improvements in both 
metabolic and histological manifestations of disease in 
subjects with nonalcoholic steatohepatitis[6].
NAFLD has the potential to progress through the inflam-
matory phase of nonalcoholic steatohepatitis (NASH) to 
fibrosis, cirrhosis (20%), and in some cases (9%) to liver 
failure or hepatocellular carcinoma (HCC) (1%) [7,8]. The 
reasons why some patients develop advanced disease 
while others have non- och less progressive liver disease 
are not fully understood. The mechanism of liver injury 
in NAFLD/NASH is suggested to be a 'two hit phenome-
non' where the 'first hit' consists in inflammation and 
development of steatosis, which sensitizes the liver to a 
variety of 'second hits' lead to fibrosis [7,9]. It is also 
increasingly recognized that fat-induced insulin resis-
tance in the liver causes activation of proinflammatory 
pathways, which will lead to modification of this 'two hit' 
process.
Identifying patients at risk for transition from hepatic ste-
atosis to NASH and fibrosis with noninvasive techniques 
are the great challenges in hepatology [9]. Therefore, 
combining of the hepatologist's knowledge of human 
hepatic pathology and pathophysiology with the endocri-
nologist's knowledge of insulin signaling and the regula-
tion of glucose and lipid metabolism in the liver will help 
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to better understand the process, and hopefully also, help 
to find new targets for the treatment and prevention of 
NAFLD.
The causal relationship between hepatic fat accumulation 
and insulin resistance
Hepatocellular steatosis is the hallmark of NAFLD. The 
histological criterion for the diagnosis of NAFLD is the 
presence of fat in more than 5% of the hepatocytes. The 
accumulation of fat usually starts in zone 3 and will in 
more severe cases may occupy whole acinus[10-12]. The 
lipid droplets in liver consist mainly in triglycerides. The 
contribution of different non-esterified fatty acids 
(NEFA) sources to hepatic triglycerides parallel to the 
VLDL triglycerides, includes: circulating NEFA pool con-
tributed 81% of hepatic and VLDL triglycerides in fasting 
conditions and 61% postprandially, dietary NEFA pool 
contributed 10% in fasting conditions and 26% postpran-
dially, whereas de novo fatty acid(DNL) contributed 7% in 
fasting and 9% postprandially[13](Fig 1).
Insulin resistance is defined as an inadequate response to 
the physiologic effects of circulating insulin in specific 
target tissues, such as skeletal muscle, liver, and adipose 
tissue,. The subjects with impaired glucose tolerance 
(IGT) demonstrate a marked muscle insulin resistance 
but only mild hepatic insulin resistance. Subjects with 
impaired fasting glucose (IFG), however, demonstrate 
severe hepatic insulin resistance but normal or near-nor-
mal muscle insulin sensitivity[14]. Epidemiological stud-
ies demonstrate that the two categories constitute two 
distinct populations, which only partially overlap, sug-
gesting that IGT and IFG represent two distinctly differ-
ent metabolic abnormalities [15]. However, it must be 
regarded as undisputable, that a strong association exists 
between insulin resistance and excess lipid accumulation 
in nonadipose tissues, particularly muscle and liver.
Although an association between NAFLD and insulin 
resistance is well accepted, it remains unclear whether 
insulin resistance causes the excessive accumulation of 
TG in liver, or it is the increase in TG itself or of its 
metabolite intermediates that plays the most causal role 
in the development of hepatic or systemic insulin resist-
ence [16]. Some investigators postulate that liver fat accu-
mulation is a result, rather than cause, of peripheral 
insulin resistance in obesity. In skeletal muscle, periph-
eral IR will primarily affect a large portion of the total 
glucose uptake (>80-90%), while in adipose tissue, insulin 
resistance will induce an impaired anti-lipolytic action of 
insulin and increased release of NEFA [17,18]. Elevated 
plasma concentrations of glucose and fatty acids may pro-
mote hepatic fatty acid and triglyceride uptake and syn-
thesis and impair β-oxidation [19]. As a result, an 
accumulation of triglycerides in the liver will occurs, 
leading to hepatic steatosis. The proposed mechanism for 
insulin resistance leading to diabetes is thus: IR in skeletal 
muscle T peripheral and portal vein hyperinsulinemia T 
hepatic steatosis T hepatic IR T DM2.
However, several observations indicate that steatosis can 
be caused also by intra-hepatic alterations in glucose and 
fat metabolism, which are independent of extrahepatic 
conditions[20,21]. Three consecutive days of feeding a 
high fat diet is known, also in the absence of significant 
peripheral fat accumulation to cause hepatic fat accumu-
lation and hepatic insulin resistance and this prior to the 
development of peripheral insulin resistence[22]. This 
study demonstrated that short term fat feeding will cause 
a 3-fold increase in liver and fatty acyl-CoA content, but 
not alter fasting plasma glucose concentration and the 
basal rate of endogenous glucose production (EGP), indi-
cating that hepatic fat accumulation from dietary NEFA 
pool is not necessarily associated with insulin resis-
tance[23].
Decreased insulin clearance has also been suggested as 
another pathway for hyperinsulinemia in liver. Insulin 
clearance is decreased in advanced liver disease, which is 
regarded as one of the main causes of hyperinsulinemia 
in iver cirrhosis [24]. The first organ to be impacted fol-
lowing insulin secretion is the liver, where a substantial 
proportion of secreted insulin is cleared via receptor 
mediated process [25,26], estimated in dogs to be app 
50% [27,28] and in humans 40-80% [25,29-32]. Both 
hepatic insulin sensitivity and whole body insulin clear-
ance were in this study measured directly by the euglyce-
mic hyperinsulinemic insulin clamp technique and liver 
fat measured by proton magnetic resonance spectroscopy 
in a group of nondiabetic subjects. The content of liver fat 
correlated significantly with impaired clearance of insulin 
(r = 0.43, P < 0.0001) and with hepatic insulin sensitivity 
(r = -0.40, P = 0.0002) [33,34]. The extent to which 
hepatic fat accumulation and impaired insulin clearance 
contribute to hyperinsulinemia can not yet be regarded as 
fully understood.
As discussed above (Fig 2), the peripheral insulin resis-
tance could well contribute to a causal role for hepatic 
steatosis, but NAFLD and hepatic insulin resistance is 
also regarded as a primary cause of of T2 MD.
The symptoms of NAFLD vary considerably from person 
to person, as some individuals may have few or no notice-
able symptoms until they are incidentally diagnosed by 
elevated levels of aminotransferase and by ultrasound. 
Other individuals will present with extremely high levels 
of hyperglycemia and classical symptoms of diabetes such 
as thirst, frequent urination, and weight loss.
The accumulation of triglycerides in liver is not equal to 
increased liver damage
Minimal histopathology criteria are used for diagnosis of 
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quantitative methods use a three-stage scale to evaluate 
the percentage of liver parenchyma occupied by steatotic 
hepatocytes: I. 0-33% (or 0-5%, 5-33%), II 33-66%and III 
more than 66%[12]. Although hepatic steatosis is a key 
component of steatohepatitis, it is not known if patients 
with greater amounts of steatosis are more likely to 
develop steatohepatitis than those with mild steatosis. 
The histological definition of steatohepatitis does not 
require a particular amount of steatosis, and, steatosis 
will often decrease and may even be completely absent in 
cases with advanced fibrosis and cirrhosis [11,35].
Several findings suggest that hepatic triglycerides per se 
are not toxic and may, in fact, even protect the liver from 
lipotoxicity by buffering the accumulation of fatty 
acid[36,37]. Yamaguchi et al [38] demonstrated that inhi-
bition of TG synthesis (mediated through the reduction 
in DGAT2 activity) will improve liver steatosis, but at a 
price of increased liver damage. Levels of hepatic fatty 
acids, cytochrome P450, and markers of lipid peroxida-
tion and oxidant stress, as well as fibrosis, were in this 
study all markedly increased, Recent findings confirm 
that the ability to synthesize triglycerides may, in fact, be 
protective in obesity. When hepatocyte triglyceride syn-
thesis is inhibited, free fatty acids will accumulate in the 
liver, and swtimulate oxidizing systems that increase 
hepatic oxidative stress and liver damage[39,40]. Further-
Figure 1 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease (Kerry L. Don-
nelly, et al, J. Clin. Invest. 2005;115:1343-1351).Liu et al. Lipids in Health and Disease 2010, 9:42
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more, feeding an n-3 PUFA-enriched diet failed to pre-
vent lipotoxic hepatocellular injury and inflammatory 
recruitment, although activated PPAR alpha and sup-
pressed hepatic de novo lipogenesis[39].
The differential toxicity of various FAs is relate directly to 
its ability to promote triglyceride accumulation[39]. The 
exogenous or endogenous generated unsaturated FAs will 
reduce palmitate-induced apoptosis by promoting palmi-
tate incorporation into triglycerides. Moreover, oleic acid, 
as well as palmitic acid, is toxic to cells with impaired 
capacity to synthesize triglycerides. Exposure of human 
hepatocytes to monounsaturated fatty acids (MUFAs) 
results in lipid accumulation without any changes in cell 
viability. In contrast, cells incubated with saturated fatty 
acids (SFAs) decrease significantly their viability in addi-
tion yo increasing their caspase activation and degree of 
apoptosis, parallel to only minor lipid droplet accumula-
tion[39].
Stearoyl-CoA desaturase-1 (SCD-1), the enzyme that 
converts SFA to MUFA, appears to provide an important 
metabolic control mechanism in the biochemistry and 
physiology of lipid metabolism. Genetic or pharmacolog-
ical inhibition of SCD1, sensitizes hepatic cells to SFA-
induced apoptosis. SCD1-/- mice on the MCD diet dem-
onstrate decreased steatosis and markedly increased 
hepatocellular apoptosis, liver injury, and fibrosis com-
pared to SCD1+/+ mice, whereas feeding MUFA pre-
vents the MCD-induced injury[41].
The studies referred to above clearly show that increased 
serum free fatty acid, rather than the excess lipid accumu-
lation in liver cells serves as a parameter of degree of liver 
damage, and might be considered as a future target for 
preventing and therapy of steatohepatitis in patients with 
NAFLD. Findings that inhibition of the expression of 
SCD-1 might also be beneficial in the treatment of obe-
sity, diabetes, and other metabolic diseases [42-45].
However, it is still quite possible that under the condi-
tions of enhanced TG synthesis, the capacity will be 
insufficient to buffer detoxifying of excess fatty acids. 
Liver damage could then occur as a result of fatty acid-
induced lipotoxicity and/or of a combination of both 
lipotoxicity and severe steatosis. A recent study shows 
that the severity of steatosis in NAFLD on histopathology 
is positively associated with lobular inflammation, zone 3 
fibrosis and definite steatohepatitis, suggesting that 
NAFLD patients with severe steatosis (affecting >66% of 
liver parenchyma) are most likely to have NASH [46]. We 
currently mainly relying on liver biopsies to confirm the 
diagnosis and indicate prognosis, as this far hepatic ultra-
sound and serum transaminases are of limited value in 
estimation of hepatic inflammation and fibrosis, How-
ever, ultrasonography is still by far the most common 
method of diagnosing NAFLD in clinical practice, espe-
cially as it has a very good sensitivity and specificity in 
detecting severe steatosis(>33% fat on liver biopsy), 
although the sensitivity of ultrasonography is not satisfac-
tory, particularly when hepatic fat infiltration is above 
33% [47,48]. The positive relationship between the sever-
ity of steatosis and other elements of NASH (i.e. inflam-
mation, ballooning, and fibrosis) provides noninvasive 
techniques to identify patients at risk for transition from 
hepatic steatosis to NASH and fibrosis. However, we are 
still unable to determine if patients with severe steatosis 
do faster progress to full blown steatohepatitis than those 
with milder forms of steatosis.
Fat-induced activation of chronic SIRS and NASH in the 
progression of NAFLD
NAFLD is a liver disease with a wide histological spec-
trum ranging from 'simple' steatosis with a generally 
benign course to nonalcoholic steatohepatitis (NASH), 
which usually is a more progressive form of the disease 
[11]. Progressive fibrosis occurs in 10-15% of patients 
with NASH and cirrhosis may develop in 15-25% of the 
cases [49,50]. Once developed, 30% to 40% of these 
patients succumb a liver-related death over a 10-year 
period [51,52], a mortality rate similar to[53,54] or worse 
than cirrhosis associated with hepatitis C. NASH-associ-
ated cirrhosis can also develop into into a subacute liver 
failure, or progress to hepatocellular cancer [55], as well 
as reoccur after liver transplantation.
Figure 2 Diagram of potential sources of and mechanisms for the 
accumulation of fat in the liver. Excess caloric intake plays a central 
role for inducing obesity and thus contributing to insulin resistance. 
Obesity may additionally impact fat accumulation in the liver by de-
creasing adiponectin levels and insulin resistance contributes to NA-
FLD directly by increasing de novo lipogenesis and indirectly by 
increasing FFA flux to the liver via decreased inhibition of lipolysis. In 
addition, excess dietary fat intake directly could also contribute to a 
causal role in hepatic steatosis(modified from Kristina M. The Journal 
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The reasons why some patients develop advanced dis-
ease, while others have indolent liver disease, are not fully 
understood. The mechanism of liver injury in NAFLD/
NASH is thought to follow, as mentioned above, a 'two hit 
pathway during which the steatosis sensitizes the liver to 
a variety of second hits, which lead to fibrosis and inflam-
mation[7]. The 'first hit', hepatic triglyceride accumula-
tion, or steatosis, increases the susceptibility of the liver 
to injury- mediated 'second hits'-changes, such as inflam-
matory cytokines/adipokines, mitochondrial dysfunc-
tion and oxidative stress, which in turn promote the 
development to steatohepatitis and/or fibrosis [9,56]. 
There is an increasing recognition of the fact that fat-
induced insulin resistance causes activation of proinflam-
matory pathways in the liver, which with time might lead 
to modification of the theory.
Most studies on the role of hepatic innate immunity in 
NAFLD has been generated by studying leptin-deficient 
(ob/ob) mice and leptin-resistant (fa/fa) rats, animals, 
which spontaneously develop fatty livers and naturally 
exhibit features, such as insulin resistance, obesity, and 
dyslipidemia, which in its turn in humans are strongly 
correlated with NAFLD [57-60]. It is increasingly docu-
mented that obesity without simultaneous inflammation 
does not result in peripheral insulin resistance, and simi-
larly, the steatosis will not lead to liver inflammation 
(NASH) and/or hepatic insulin resistance [57]. Wild type 
mice fed a high-fat diet, will normally develop obesity 
with simultaneous inflammation, insulin resistance and 
mild Type 2 diabetes. On the contrast, chimerical mice, 
lacking immune cells will become obese, but have a strik-
ing absence of insulin resistance. In addition, their livers 
will remain normal [61-63]. Among the proinflammatory 
molecules, TNF-α has been proposed to be the key link 
between obesity and insulin resistance. TNF-α is usually 
over- expressed in adipose tissues of obese animals and 
humans, and obese mice lacking TNF-α and/or its recep-
tor demonstrate protection against development of insu-
lin resistance[64,65].
To date, many lines of evidence seem to show that in 
humans chronic activation of proinflammatory pathways 
of insulin targetted cells can result in obesity/steatosis -
related insulin resistance. The influence of circulating 
and hepatic levels of proinflammatory cytokines TNF-α, 
IL-6, and C-reactive protein (CRP) in patients with 
NAFLD and their correlation with disease severity are 
well studied. Patients with NASH have generally signifi-
cantly higher levels of serum TNF-α and IL-6 than seen in 
patients with simple steatosis. NASH is, when compared 
to simple steatosis, associated with higher levels of solu-
ble TNF receptor 1 (sTNFR1) and soluble IL-6 receptor 
(sIL-6R) [66,67]. In addition, the expression is higher in 
those patients with more severe NASH. The findings that 
inflammation and insulin resistance often seem to occur 
in parallel and to reinforce each other via positive feed-
back mechanisms, suggesting that disruption of the inter-
face between inflammatory and metabolic pathways is 
central in the pathogenesis and progression (second hit) 
of NAFLD and also increase the risk of development of 
insulin resistance (Type 2 diabetes). Given the role of 
TNF-α in inducing both necroinflammation and IR, anti-
TNF agents have been considered for treatment of 
NASH. Reducing TNF-α signaling either by TNF-α 
knocking out mechanisms or by infusion of blocking anti-
bodies reduces insulin resistance in obese rodents [68]. 
Pentoxifylline, a TNF-α inhibitor, has also been used for 
the same purpose in patients with NASH. Two smaller 
studies in NASH patients report significant improve-
ments in AST and ALT and also significant improvement 
in insulin resistant after pentoxyfylline treatment [69,70], 
supporting the hypothesis that anti-inflammatory treat-
ments have favorable effects on NASH. However, TNF-α 
antibody treatment will not alter insulin sensitivity in 
humans [71]. Attempts in this study to over a period of 4 
weeks neutralize TNF-alpha with an engineered human 
anti-TNF-alpha antibody (CDP571) had no effect on 
insulin sensitivity in obese non-insulin-dependent diabe-
tes subjects with rheumatic diseases.
Fat can cause insulin resistance by prompting the activa-
tion of select serine kinases within a variety of insulin 
sensitive cells. The three serine kinases most strongly 
implicated in the pathogenesis of fat-induced insulin 
resistance are Jun N-terminal kinase (JNK), inhibitor of 
nuclear factor κB (NF-κB) kinase(IKK), and novel iso-
forms of protein kinase C (PKC) [72-74]. These enzymes 
will, alone or in combination, phosphorylate regulatory 
serine residues on the insulin receptor substrates IRS-1 
and IRS-2, leading to the downmodulation of normal 
insulin-stimulated tyrosine phosphorylation and interfer-
ing with physiologic insulin [57]. Among these, JNK and 
IKK are significantly effective proinflammatory signaling 
molecules. IKK and JNK cause inflammation by promot-
ing formation of the transcription factors AP-1 and NF-
κB, which activate transcription of a multitude of proin-
flammatory genes, cytokines, chemokines, and cell adhe-
sion molecules[75]. A causal connection between fat-
related activation of serine kinases and insulin resistance 
has been demonstrated in adipose tissue [76] and muscle 
[77] as well as liver [78-81]. Mice heterozygous for IKKβ 
are protected against the negative effects of a high-fat 
diet-associated obesity as well as development of insulin 
resistance [82]. Silencing of IKKβ will also prevent TNF-
alpha-induced impairments in the action of insulin on 
Akt phosphorylation and glucose uptake in primary 
human skeletal muscle myotubes from non-diabetic sub-
jects [83,84].
Also, fatty acids and high-fat feeding can, even in the 
absence of obesity or systemic insulin resistance, directly Liu et al. Lipids in Health and Disease 2010, 9:42
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induce inflammatory signaling through mammalian toll-
like receptors (TLRs) in the liver [85,86]. TLRs are cellu-
lar pattern-recognizing receptors (PRRs) that recognize 
the molecular patterns of pathogens, such as Gram-nega-
tive endotoxin. After engaging the pathogenic patterned 
ligands via a receptor-driven signaling cascade do they 
activate the transcription factor NF-κB, resulting in 
increased expression of proinflammatory cytokines, 
which in its turn trigger inflammation. Such rapid, innate 
cellular responses serve as the first line of host defense 
against infection by pathogens. Increasing evidence sug-
gests that TLRs also recognize host-derived ligands and 
interact with these endogenous ligands, generating tissue 
injury and cell death [87]. Thus TLRs will act as PRRs that 
paralle with the lipotoxicity and stress of endoplasmic 
reticulumt, use signaling mechanisms to solicit inflam-
mation and fat-induced insulin resistance (Fig 3). Such 
efforts should also reveal a wealth of potential targets for 
interventions and drug development that prevent 
NASH[88]. Probiotics, which reportedly suppress TLR-
related responses by altering the intestinal flora [89,90], 
reduce inflammation and improve the liver in animals 
and humans with fatty livers[91,92]. Similarly, dietary n-3 
polyunsaturated fatty acids, which are known inhibitors 
of TLR signaling[93], will have the capacity to suppress 
necro-inflammation and fibrosis in experimental fatty 
liver disease[94].
FoxO1 is a forkhead transcriptional factor that acts to 
mediate insulin action on target gene expression in 
peripheral cells [95-97]. More recent studies show that 
FoxO1 signaling through NF-kB plays a significant role in 
proinflammatory cytokine production and insulin resis-
tance (Fig 4). FoxO1 stimulate selectively macrophage 
production of IL-1β, but not IL-6, TNFα, and IFN-γ.
FoxO1 is known to mediate the inhibitory effect of insu-
lin on target gene expression. In the absence of insulin, 
FoxO1 acts in the nucleus as an enhancer of target gene 
expression, whereas in the presence of insulin, FoxO1, 
phosphorylated by Akt/PKB, will contribute to inhibition 
of target gene expression. The phosphorylation-depen-
dent protein trafficking mechanism is crucial for the reg-
ulation of FoxO1 transcriptional activity within cells [98-
100]. The IL-1β promoter contains sites for both FoxO1 
and NFkB target that are juxtapositioned within the pro-
moter-proximal region of the Il1b gene in mice, rats and 
humans, implying evolutionally conserved mechanisms 
or FoxO1 signaling through the NFkB pathway in regula-
tion of proinflammatory cytokines. Amelioration of insu-
lin resistance with blockage of IL-1β signaling via its 
receptor antagonist is associated with improving diabetes 
[101].
Conclusion
The molecular mechanisms underlying NAFLD and 
treatment options are this far poorly understood. Clearly, 
numerous factors are associated with increased activa-
tion of hepatic innate immune system, which is central to 
the development of fat-related insulin resistance and also 
plays an important role in fat-related liver damage 
(NASH). NASH is seemingly a much multifactorial con-
dition with some pathological end points such as 
increased hepatic oxidative stress, increased hepatic 
cytokine expression, direct "lipotoxicity" of excess circu-
Figure 4 Convergence of the FoxO1 and NFκB pathways in IL-1β 
gene expression: FoxO1 targets at the IRE DNA motif of the IL-1β 
promoter for trans-activation. This effect along with the activation 
of the NFκB pathways synergistically promotes macrophage produc-
tion of proinflammatory cytokine IL-1β. (Dongming Su et al. FoxO1 
Links Insulin Resistance to Proinflammatory Cytokine IL-1beta Produc-
tion in Macrophages. in Press).
Figure 3 Activation of inflammatory signaling pathways by 
fat(Hepatology. 2008;48:670-8).Liu et al. Lipids in Health and Disease 2010, 9:42
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lating NEFAs and insulin resistance. Especilly are the ser-
ine kinases key factors in the development of insulin 
resistance within hepatocytes and in other insulin sensi-
tive cells. Especially IKK and JNK, are important compo-
nents what is described as the two major 
proinflammatory pathways.
Future exploration of the signaling routes from fat to NF-
κB might provide information about hitherto unknown 
etiological factors behind chronic diseases in addition to 
those already known. It might also provide information 
about potentially new targets for drug development and 
treatment of these diseases.
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